A sponsor-focused guide to clinical trials in Latvia; covering EU-aligned regulation, Riga's university hospital network, treatment-naïve patient populations, and the Baltic State's role in efficient multi-country European programmes.
Tucked between the Baltic Sea and the Russian border, Latvia punches well above its weight in clinical research. For a country of just 1.8 million people, it has ranked among the top five nations globally for interventional clinical trial registrations per million population; a distinction that reflects deep institutional investment in research-ready healthcare rather than chance.
Latvia is the middle of the three Baltic States, wedged between Estonia to the north and Lithuania to the south, with Riga as its capital and largest city; home to about 640,000 people. The country's history; Germanic crusader rule, Swedish and Russian empires, Soviet occupation, and a hard-won independence regained in 1990; left behind a healthcare system built on the Soviet model of highly centralised, physician-led care. When Latvia entered the EU in 2004, that legacy proved surprisingly useful: centralized systems are easier to reform and harmonize with EU clinical trial regulations than fragmented ones.
Today Latvia is a modern EU member state with a universal public health system, a strong network of university hospitals, and a population that trusts its physicians deeply; a cultural trait that directly benefits clinical trial recruitment.
Geographic concentration: Riga is the primary hub for clinical trials. Regional centres include Daugavpils, Liepāja, Valmiera, and Rēzekne; collectively giving sponsors near-complete national coverage from a small number of well-connected sites.
Latvia's population of approximately 1.8 million is predominantly urban; around 68% of residents live in cities. The largest age cohort (about 41%) falls between 25 and 54, providing a strong working-age participant pool for a wide range of therapeutic indications. Life expectancy sits at 75.7 years.
Latvia's ethnic composition is one of the more diverse in Northern Europe. The substantial Russian-speaking minority; a legacy of Soviet-era migration; means investigators are often bilingual, and patient populations reflect both Baltic and Eastern Slavic genetic backgrounds. This makes Latvia particularly valuable in studies targeting cardiovascular and metabolic conditions, which carry different incidence profiles across these populations.
"Latvia's physician-patient relationships are characterized by a high level of trust; a cultural dynamic that translates into faster consent processes, better retention, and lower dropout rates in clinical trials."
Latvia offers a rare combination: full EU regulatory alignment, treatment-naïve patient populations in cardiovascular and oncology, a high-trust physician-patient culture, bilingual investigator teams, and a cost base well below Western European sites.
Full EU alignment since 2004; ICH-GCP codified in national law; State Agency of Medicines (ZVA) and Central Medical Ethics Committee (CMEC) operating within a 60-day approval window; CTR / CTIS adoption streamlining multi-country submissions.
Cost base meaningfully below Western European comparators; lean operational footprint; competitive investigator fees; compact Riga hub enabling efficient multi-site coordination across the Baltics.
1.8M people; ethnically diverse with Latvian and Russian-speaking cohorts; treatment-naïve populations across cardiovascular, oncology, and metabolic disease; high physician-patient trust supporting fast consent and low dropout.
Riga Stradiņš University and University of Latvia anchor the investigator pipeline; well-equipped university hospitals with CT, MRI, and advanced laboratory capacity; bilingual (Latvian / Russian) investigator teams; English fluency among younger physicians.
Latvia has established itself as a reliable, cost-effective destination for Phase I–IV studies within the EU regulatory framework. Since joining the EU in 2004, the country harmonized its legislation with EU Directives 2001/20 and 2005/28 and incorporated ICH-GCP guidelines into national law. The Central Medical Ethics Committee (CMEC) oversees ethical review, and the State Agency of Medicines (ZVA) acts as the competent authority; both operating within a 60-day approval timeline.
Historically, oncology led trial activity in Latvia, reflecting the Baltic States' elevated incidence of cancer and cardiovascular disease relative to Western EU averages. Pulmonology and allergy have also been significant therapeutic areas. In recent years, the landscape has broadened to include rheumatology, neurology, gastroenterology, and infectious diseases; aided by Latvia's capacity for treatment-naïve patient populations, a key advantage for first-line indication studies.
The following institutions are Latvia's primary sites for clinical research, spanning university hospitals, specialized centres, and regional facilities.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Pauls Stradiņš Clinical University Hospital | Riga | Latvia's largest university hospital; cardiology, oncology, neurology, and transplantology research. |
| 02 | Riga East University Hospital (Gaiļezers) | Riga | Infectious disease, pulmonology, stem cell transplantation, and oncology trials. |
| 03 | Oncology Centre of Latvia (Riga East) | Riga | National cancer centre; oncology trials and radiation therapy programmes. |
| 04 | Children's Clinical University Hospital | Riga | Latvia's only tertiary pediatric centre; oncology, cardiology, and rare disease trials. |
| 05 | Latvian Centre of Infectious Diseases (Riga East) | Riga | HIV / AIDS, hepatitis, and complex infectious disease studies. |
| 06 | Centre of Tuberculosis and Lung Diseases | Riga | Respiratory trials including drug-resistant tuberculosis. |
| 07 | Riga East University Hospital — Biķernieki | Riga | Microsurgery, burns, toxicology, and rehabilitation research. |
| 08 | Hospital of Traumatology and Orthopaedics | Riga | Musculoskeletal trials; joint replacement and spinal surgery. |
| 09 | Riga 1st Hospital | Riga | Multidisciplinary; surgery, ophthalmology, urology, and internal medicine. |
| 10 | Riga Maternity Hospital | Riga | Obstetrics, gynecology, and neonatology; Latvia's largest maternity centre. |
| 11 | Daugavpils Regional Hospital | Daugavpils | Major regional centre serving Latgale; multi-specialty research. |
| 12 | Liepāja Regional Hospital | Liepāja | Key western Latvia centre; maternity, surgery, and internal medicine. |
| 13 | Riga Psychiatry and Narcology Centre | Riga | CNS and psychiatry trials; Latvia's largest mental health institution. |
| 14 | Vidzeme Hospital | Valmiera | Regional centre serving northern Latvia; multi-specialty programmes. |
| 15 | Capital Clinic Riga | Riga | Private multi-specialty clinic; cardiology, neurology, and diagnostics. |
Latvia's largest university hospital; cardiology, oncology, neurology, and transplantology research.
Infectious disease, pulmonology, stem cell transplantation, and oncology trials.
National cancer centre; oncology trials and radiation therapy programmes.
Latvia's only tertiary pediatric centre; oncology, cardiology, and rare disease trials.
HIV / AIDS, hepatitis, and complex infectious disease studies.
Respiratory trials including drug-resistant tuberculosis.
Microsurgery, burns, toxicology, and rehabilitation research.
Musculoskeletal trials; joint replacement and spinal surgery.
Multidisciplinary; surgery, ophthalmology, urology, and internal medicine.
Obstetrics, gynecology, and neonatology; Latvia's largest maternity centre.
Major regional centre serving Latgale; multi-specialty research.
Key western Latvia centre; maternity, surgery, and internal medicine.
CNS and psychiatry trials; Latvia's largest mental health institution.
Regional centre serving northern Latvia; multi-specialty programmes.
Private multi-specialty clinic; cardiology, neurology, and diagnostics.
Latvia's clinical trial ecosystem is supported by a network of regulatory bodies, academic institutions, and CROs operating across the Baltic region.
National competent authority for clinical trial authorization; operates within a 60-day approval timeline; aligned with EU CTR via CTIS.
The sole ethics body for clinical trial review in Latvia; coordinates ethical oversight across all sites.
Latvia's primary medical university; trains investigators and hosts research departments across therapeutic areas.
Co-affiliated with Pauls Stradiņš Hospital for clinical research; complements the RSU investigator pipeline.
Organizes GCP training for Latvian investigators; supports compliance with ICH-GCP standards.
Leading Eastern European CRO with active Latvia operations; oncology, gastroenterology, and infectious disease focus.
Baltic-focused CRO; Phase I–IV programmes across the Baltic States and Caucasus.
Functional outsourcing and site management; deep Latvia, Estonia, and Lithuania presence.
Finland-based CRO with a strong Latvia network; regulatory and monitoring services.
Eastern European CRO managing Baltic States trial portfolios.
For sponsors evaluating clinical trials in Latvia, the opportunity is defined by EU regulatory alignment, investigator depth, treatment-naïve patient access, and fit within a wider Baltic and CEE clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
Whether you are planning a first-in-class oncology study or a Phase III cardiovascular trial, Latvia's lean, motivated research infrastructure makes it a smart inclusion in any European site strategy. EU membership since 2004 delivers a harmonized regulatory and legislative environment, fast enrollment, and a patient population with high rates of cardiovascular and oncological disease; precisely the indications driving global trial demand.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.